|ALPHARX INC. Patent applications|
|Patent application number||Title||Published|
|20110070305||SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MEBICAR - The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders.||03-24-2011|
|20100129431||IDEBENONE COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.||05-27-2010|
|20100099775||METHOD FOR AMELIORATING OF POST-ANESTHETIC RECOVERY - The invention describes use of injectable form of Idebenone to improve recovery after general anesthesia and of cognitive functions, suppress disorientation and other signs of neuronal damage.||04-22-2010|
|20090169635||PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and a decrease in frequency of the drug administration. Antibiotics of various types, such as aminoglycosides, glycopeptides and others can be successfully incorporated into a nanoparticulate colloidal delivery system.||07-02-2009|
Patent applications by ALPHARX INC.